

## **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA390)**

**NICE GUIDANCE ISSUED MAY 2016**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

**Advice No: 3915 – December 2015**

**Empagliflozin (Jardiance<sup>®</sup>▼)**

**10 mg and 25 mg film-coated tablets**

**Submission by Boehringer Ingelheim Ltd**

### **Recommendation of AWMSG**

**Empagliflozin (Jardiance<sup>®</sup>▼) is recommended as an option for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as:**

**Monotherapy. When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.**

#### **Additional note(s):**

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2746), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3915:  
Empagliflozin (Jardiance<sup>®</sup>) 10 mg and 25 mg film-coated tablets. December 2015.

